CN100584856C - The purposes of a kind of Hederagenin, its preparation method and preparation antitumor drug thereof - Google Patents
The purposes of a kind of Hederagenin, its preparation method and preparation antitumor drug thereof Download PDFInfo
- Publication number
- CN100584856C CN100584856C CN200710135566A CN200710135566A CN100584856C CN 100584856 C CN100584856 C CN 100584856C CN 200710135566 A CN200710135566 A CN 200710135566A CN 200710135566 A CN200710135566 A CN 200710135566A CN 100584856 C CN100584856 C CN 100584856C
- Authority
- CN
- China
- Prior art keywords
- compound
- cheng
- preparation
- saponin
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 9
- 229940041181 antineoplastic drug Drugs 0.000 title claims abstract description 8
- NTWLPZMPTFQYQI-UHFFFAOYSA-N (3alpha)-olean-12-ene-3,23-diol Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC3C21C NTWLPZMPTFQYQI-UHFFFAOYSA-N 0.000 title description 4
- GCGBHJLBFAPRDB-UHFFFAOYSA-N Hederagenin Natural products CC1(C)CCC2(CCC3(C)C4CCC5C(C)(CO)C(O)CCC5(C)C4CC=C3C2C1)C(=O)O GCGBHJLBFAPRDB-UHFFFAOYSA-N 0.000 title description 4
- GCGBHJLBFAPRDB-KCVAUKQGSA-N Scutellaric acid Natural products CC1(C)CC[C@@]2(CC[C@@]3(C)[C@@H]4CC[C@H]5[C@@](C)(CO)[C@H](O)CC[C@]5(C)[C@H]4CC=C3[C@@H]2C1)C(=O)O GCGBHJLBFAPRDB-KCVAUKQGSA-N 0.000 title description 4
- PGOYMURMZNDHNS-MYPRUECHSA-N hederagenin Chemical compound C1C[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C PGOYMURMZNDHNS-MYPRUECHSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 43
- 238000000605 extraction Methods 0.000 claims abstract description 12
- 238000000926 separation method Methods 0.000 claims abstract description 7
- 229930182490 saponin Natural products 0.000 claims description 31
- 235000017709 saponins Nutrition 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 150000007949 saponins Chemical class 0.000 claims description 26
- 241000245240 Lonicera Species 0.000 claims description 24
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 239000011347 resin Substances 0.000 claims description 9
- 229920005989 resin Polymers 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- -1 saponin compound Chemical class 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 6
- 238000010898 silica gel chromatography Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000000703 high-speed centrifugation Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 13
- 230000007062 hydrolysis Effects 0.000 abstract description 13
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 13
- 229940002612 prodrug Drugs 0.000 abstract description 5
- 239000000651 prodrug Substances 0.000 abstract description 5
- 241001570521 Lonicera periclymenum Species 0.000 abstract description 4
- 150000008130 triterpenoid saponins Chemical class 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 11
- 230000000259 anti-tumor effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- IAGSHEHQJJTLLR-FNINEVAMSA-N (4as,6ar,6as,6br,8ar,9r,10s,12ar,14bs)-10-[(2s,3r,4s,5s)-3-[(2s,3r,4r,5s,6s)-3,5-dihydroxy-6-methyl-4-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl]oxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10, Chemical compound O([C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H](OC[C@H](O)[C@@H]2O)O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(CC[C@]6(CCC(C)(C)C[C@H]6C5=CC4)C(O)=O)C)(C)CC3)(C)CC2)(C)CO)O[C@H]([C@@H]1O)C)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O IAGSHEHQJJTLLR-FNINEVAMSA-N 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- IAGSHEHQJJTLLR-UHFFFAOYSA-N sapindoside B Natural products OC1C(C)OC(OC2C(OCC(O)C2O)OC2C(C3C(C4C(C5(CCC6(CCC(C)(C)CC6C5=CC4)C(O)=O)C)(C)CC3)(C)CC2)(C)CO)C(O)C1OC1OCC(O)C(O)C1O IAGSHEHQJJTLLR-UHFFFAOYSA-N 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229960000641 zorubicin Drugs 0.000 description 5
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229960001866 silicon dioxide Drugs 0.000 description 4
- 229960003487 xylose Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 244000167230 Lonicera japonica Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 229960004679 doxorubicin Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 229930195624 Fulvotomentoside Natural products 0.000 description 2
- 241001500894 Lonicera fulvotomentosa Species 0.000 description 2
- 235000017617 Lonicera japonica Nutrition 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- SRBFZHDQGSBBOR-QMKXCQHVSA-N alpha-L-arabinopyranose Chemical compound O[C@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-QMKXCQHVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- PBUWCVBYMDVPCL-UHFFFAOYSA-N 3-anilinophthalic acid Chemical compound OC(=O)C1=CC=CC(NC=2C=CC=CC=2)=C1C(O)=O PBUWCVBYMDVPCL-UHFFFAOYSA-N 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- YRMVSUWAPZCCAP-UHFFFAOYSA-N Fulvotomentoside A Natural products OC1C(OC2C(C(O)C(O)CO2)O)C(O)C(C)OC1OC1C(O)C(O)COC1OC(C1(C)CO)CCC2(C)C1CCC(C1(CC3)C)(C)C2CC=C1C1CC(C)(C)CCC13C(=O)OC(C(C1O)O)OC(CO)C1OC1OC(CO)C(O)C(O)C1O YRMVSUWAPZCCAP-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000100289 Lonicera confusa Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 description 1
- KEOITPILCOILGM-FCWYPSSHSA-N Sapindoside A Natural products O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H]([C@@](CO)(C)[C@@H](O[C@@H]6[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O7)[C@H](O)[C@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2 KEOITPILCOILGM-FCWYPSSHSA-N 0.000 description 1
- UODCQSBZHQZMEW-NDVYAFTQSA-N [(2s,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl] (4as,6ar,6as,6br,10s,12ar,14br)-9-(hydroxymethyl)-10-[(2s,3r,4s,5s)-5-hydroxy-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)[C@@H](O)CO[C@H]1O[C@@H]1C(CO)(C)C(CC[C@@]2(C)[C@@]3(CC[C@]4(CCC(C)(C)C[C@@H]4C3=CC[C@H]32)C(=O)O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@@H](CO)O2)O)C)[C@]3(C)CC1 UODCQSBZHQZMEW-NDVYAFTQSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- KBYYTUYPCGPQNK-UHFFFAOYSA-N alpha-hederin Natural products CC1OC(OC2C(O)C(CO)OC2OC3CCC4(C)C(CCC5(C)C4CC=C6C7CC(C)(C)CCC7(CCC56C)C(=O)O)C3(C)CO)C(O)C(O)C1O KBYYTUYPCGPQNK-UHFFFAOYSA-N 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- YDXWQWMRQORSTI-UHFFFAOYSA-N decaisoside D Natural products OC1C(OC2C(C(O)C(O)CO2)O)C(O)C(C)OC1OC1C(O)C(O)COC1OC(C1(C)CO)CCC2(C)C1CCC(C1(CC3)C)(C)C2CC=C1C1CC(C)(C)CCC13C(=O)OC1OC(CO)C(O)C(O)C1O YDXWQWMRQORSTI-UHFFFAOYSA-N 0.000 description 1
- DQDTUCJCIHGIOL-UHFFFAOYSA-N decaisoside E Natural products OC1C(OC2C(C(O)C(O)CO2)O)C(O)C(C)OC1OC1C(O)C(O)COC1OC(C1(C)CO)CCC2(C)C1CCC(C1(CC3)C)(C)C2CC=C1C1CC(C)(C)CCC13C(=O)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O DQDTUCJCIHGIOL-UHFFFAOYSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000005858 glycosidation reaction Methods 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- KEOITPILCOILGM-LLJOFIFVSA-N kalopanaxsaponin A Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@@]([C@H]3[C@]([C@@H]4[C@@]([C@@]5(CC[C@]6(CCC(C)(C)C[C@H]6C5=CC4)C(O)=O)C)(C)CC3)(C)CC2)(C)CO)OC[C@H](O)[C@@H]1O KEOITPILCOILGM-LLJOFIFVSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to natural medicine field, be specifically related to a kind of compound of extraction separation (I) from woodbine Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms bud, its skeleton belongs to ivy type triterpenoid saponin; The invention still further relates to the preparation method of this compound and basic hydrolysis product thereof, and this compound is as the application of prodrug in the preparation antitumor drug.
Description
Technical field
The present invention relates to natural medicine field, be specifically related to a kind of compound of extraction separation from woodbine Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms bud, its skeleton belongs to ivy type triterpenoid saponin; The invention still further relates to the preparation method of this compound and basic hydrolysis product thereof, and this compound is as the application of prodrug in the preparation antitumor drug.
Background technology
Malignant tumour is one of major disease of serious harm human health.The control of tumour has become the problem of extensively paying attention in the world wide, and the development of antitumor drug also has extremely exigence with exploitation.Plant is the preciousness source of new bioactive molecules, seeks the attention that the new medicine with anti-tumor activity more and more is subjected to medical worker from plant origin.Many cancer therapy drugs from plant, have been isolated, as vincristine(VCR), epipodophyllotoxin glucoside and taxol etc.With respect to the chemicals of synthetic, the effective constituent of these natural origins has obtained a large amount of application with the lower advantage of its toxicity in oncotherapy.
Saponin(e is extensively to be present in the special glycoside of a botanic class, and wherein sapogenin is that the saponin(e of the triterpenes derivative formed of 30 carbon atoms is called triterpenoid saponin.Modern study shows, saponin component has physiologically active widely, except the effect of direct killing and inhibition tumour cell, saponin(e in the transfer of startup, the evolution that delays cancer of enhancing body immunologic function, containment cancer, anticancer, suppress tumor-blood-vessel growth, the many aspects such as result of treatment that improve traditional clinical anticarcinogen have good activity, prompting research and development anti-cancer agent from saponin(e has wide prospect.
Japanese Honeysuckle is the dry flower (2005 version " Chinese pharmacopoeia) of Caprifoliaceae woodbine honeysuckle Lonicerajaponica Thunb., is China's conventional Chinese medicine.Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms is the dry flower of Caprifoliaceae woodbine L.fulvotomentosa Hsu et S.C.Cheng.Its crude drug source is the woodbine novel species of finding in state, the southwest of Guizhou Province in the later stage seventies 20th century, is Chinese endemic plant kind, mainly is distributed in Guizhou, Guangxi, Yunnan San Sheng and aboundresources.Effects such as that the Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms bud has is clearing heat and detoxicating, wind-heat dissipating, the medicinal history more than existing 5 generation people among the people is mainly used in treatment hepatitis, stomach trouble, flu etc., and the effect of relieving the effect of alcohol is arranged.Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms is Guizhou Province's provincial standard kind, is one of regional Japanese Honeysuckle commodity medicinal material main flow kinds such as Guizhou, Guangxi also, and " the Chinese pharmacopoeia [is listed in one of Lonicera confusa DC. medicinal material base source plant to be included into version in 2005.
Be rich in the Hederagenin constituents in the Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms bud, content is up to about 20%.Forefathers find the pharmacological research of Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms total saponins, its have good protect the liver, anti-inflammatory isoreactivity, the particularly liver injury that multiple mechanism of action and different chemical toxicants are caused all have provide protection in various degree.Yet the study of pharmacy to its saponin component is also less, isolation identification Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms saponin(e first (fulvotomentoside A), sapindoside B (sapindoside B) and α-Hederagenin (three kinds of saponin components of α-hederin), but the content of these several effective constituents in plant is extremely low have only been reported therefrom at present.
Summary of the invention
The present invention utilizes modern separation technology and structure identification of means that the Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms bud is carried out chemical constitution study, therefrom separates obtaining a kind of new Hederagenin Compound I, and this compound content in medicinal material is extremely abundant, and content is up to about 5%.Find that by the anti tumor activity in vitro screening this compound does not show activity, but its basic hydrolysis product has very strong inside and outside anti-tumor activity.Because this new compound aboundresources, hydrolysate is active clear and definite, and technology is simple and easy to do, and efficiency of pcr product and purity height can be used as the prodrug for preparing antitumor activity component, are fit to industrial mass production, and market outlook and exploitation with Guan Kuo are worth.
Compound I structure of the present invention is as follows:
R wherein
1, R
2, R
3In one be xylosyl (Xyl '), two is H in addition.Be glucosyl group (Glc) and wood sugar (Xyl ') can be the 1-2 position, 1-4 position or 1-6 position connect.
Preferred compound is:
Compound III: molecular formula is C
57H
92O
25, its molecular weight is 1176,214～215 ℃ of m p, [α]
D 20-37.35 ° (c 0.5, MeOH).Chemical name: 3-O-β-D-xylopyranosyl (1 → 3)-α-L-rhamnopyranosyl (1 → 2)-α-L-arabopyranose base hederagenin-28-O-β-D-xylopyranosyl (1 → 4)-β-D-glucopyranosyl ester glycosides, called after Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms saponin(e second (fulvotomentoside B).
Compound I of the present invention is the medicine prodrug, and itself does not have activity, but produces the medicine of the activeconstituents that can bring into play the expection drug effect in body by hydrolysis, metabolism, approach such as derive.
Compound of Formula I of the present invention can prepare with following method:
With the Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms dry flower is raw material, with the 30-90% alcohol reflux, extracting solution is evaporated to does not have the alcohol flavor, filter or high speed centrifugation, macroporous resin column on filtrate or the centrifuged supernatant is fully after the absorption, with alcohol-water system gradient elution, merge 50-70% ethanol liquid elutriant, evaporated under reduced pressure obtains the Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms total saponins.Total saponins is again through silica gel column chromatography, anti-phase C18 post and the further separation and purification of dextrane gel column chromatography, promptly.
More preferably the preparation method is: getting the Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms dry flower is raw material, with the 50-90% alcohol reflux, extracting solution is evaporated to does not have the alcohol flavor, filter or high speed centrifugation, after macroporous resin fully adsorbs on filtrate or the centrifuged supernatant, successively water, 30% ethanol, that 70% ethanol liquid is eluted to elutriant is closely colourless, collect 70% ethanol liquid elutriant, evaporated under reduced pressure, obtain the Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms total saponins, total saponins is again through silica gel (200-300 order), anti-phase C18 post and the further separation and purification of dextrane gel column chromatography, get final product Compound I.The wherein preferred D101 of macroporous resin, AB-8, HPD100, HPD300 or D1 type macroporous resin.D101 type macroporous resin most preferably.
Compound I can add acetylation reagent and form acetylate, perhaps as required, adds other reagent and forms new derivative, can also utilize the effect of bioactive enzyme, changes link position, changes over 1-4 or 1-2 connection as being connected by 1-6.
Compound I of the present invention, antitumor activity in vitro does not show activity.But Compound I of the present invention can change into the secondary saponin Compound I I with anti-tumor activity by 28 sugar ester keys of basic hydrolysis.
Compound I I: molecular formula is C
46H
74O
16, its molecular weight is 882,224～226 ℃ of m p.Chemical name: hederagenin-3-O-β-D-xylopyranosyl-(1 → 3)-α-L-rhamnopyranosyl-(1 → 2)-α-L-arabopyranose glycosides, i.e. sapindoside B.
Compound I can prepare Compound I I by the method for hydrolysis that those skilled in the art use always, also available following method preparation:
Compound I adds 1～8% potassium hydroxide or aqueous sodium hydroxide solution, and warm or refluxing extraction 2～6h in 40～80 ℃ of water-baths adds sour adjust pH to 4～6 after cold.Use n-butanol extraction again, extraction liquid carries out silica gel column chromatography after reclaiming solvent, uses ethyl acetate: methyl alcohol: the water system wash-out, concentrate, and get white powder Compound I I.Ethyl acetate wherein: methyl alcohol: water preferred volume ratio 5: 1: 0.1.Prove that through pharmacological testing Compound I I has good anti-tumor effect.
Because the Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms plant resources is very abundant, and the content of this new compound in the Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms bud is up to about 5%, and the source is sufficient; Step by the active secondary saponin II of this compound is easy, 28 sugar ester keys of hydrolysis and do not destroy 3 sugar chains only, overcome the shortcoming of acid hydrolysis products complexity, separation and purification difficulty, purpose is strong, transformation efficiency is high, therefore can be used as prodrug and uses in the preparation antitumor drug.
Be part pharmacology test of the present invention and result below:
One, the external restraining effect of new compound I of the present invention and hydrolysate Compound I I thereof to tumour cell:
1) clone and reagent: human lung cancer cell A549, human cervical carcinoma cell Hela, melanoma cell B16, breast cancer cell MDA-MB-231.The DMEM high glucose medium is available from U.S. Gibco company.Calf serum, non-essential amino acid are available from Hyclone company.Trypsinase, MTT reagent are available from Sigma company.
2) be subjected to the reagent thing: separate obtaining in the bud of Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms saponin(e second (I) by Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms L.fulvotomentosa Hsu et S.C.Cheng.Sapindoside B (II) is prepared by the hydrolysis of Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms saponin(e second.The positive control medicine is Zorubicin (Doxorubicin).
3) cell cultures: 4 kinds of tumour cells all with the DMEM nutrient solution that contains 10% calf serum in 37 ℃, 5%CO
2And cultivate under the saturated humidity condition.The cell in good condition in vegetative period of taking the logarithm is used 0.25% tryptic digestion, makes cell suspension, counts about 5 * 10
4Individual/mL, to inoculate into 96 orifice plates by 5000 the cell obtained cell suspensions in every hole, 100 μ L/ holes place in the cell culture incubator and cultivated 24 hours; The administration group is handled with the Compound I or the II of different concns, and the medicine final concentration is 2,4,8,16,32 μ M/mL.With the negative control group of the nutrient solution that contains 0.02% methyl-sulphoxide,, answer holes for 6 every group simultaneously with the positive control group of Zorubicin.Cultivate after 48 hours, the observation of cell form, every hole adds MTT solution (5mg/mL) 10 μ L, hatch 4 hours under 37 ℃ after, the careful suction abandoned the culture supernatant hole in, every hole adds 100 μ L DMSO, the 3min that vibrates fully dissolves crystallization.Select the 570nm wavelength, on microplate reader, measure each hole absorbance value (OD value), get 3 multiple hole OD value mean numbers, be calculated as follows cell inhibitory rate:
Cell inhibitory rate (%)=(negative control group OD value one is tried thing group OD value)/negative control group OD value * 100%
The results are shown in Table 1, table 1 shows that new compound I of the present invention does not show anti-tumor activity, but the basic hydrolysis product of different concns all possesses stronger growth-inhibiting effect to 4 kinds of cancer cells.
Table 1 new compound I of the present invention and basic hydrolysis product Compound I I thereof are to the ED of different tumor cell lines
50(μ M)
Two, the anti-tumor in vivo pharmacodynamic study of The compounds of this invention II
1) foundation of animal model for tumour: female C57BL/6J mouse, age in 6-8 week, one-level, body weight 18 ± 2g.The solid tumor models that this experiment is set up is the Lewis lung cancer model.Get the tumour cell of exponential phase of growth, after trysinization, wash twice with PBS, it is subcutaneous that cell is subcutaneously injected into C57BL/6J right side of mice back, every mouse inoculation of LLC tumor model 1 * 10
6Individual tumour cell (50 μ l), visible tumor in situ after about 5 days, when treating that diameter of tumor reaches the 5mm left and right sides animal is divided into 5 groups at random, promptly sapindoside B group (being 6 μ M/kg), Zorubicin (Doxorubicin) group and control group (Control) reach more than 8 every group of mouse.Every day, intraperitoneal injection was 1 time, continued 7 days, and control group is in intraperitoneal injection equal-volume PBS.Detect mouse body weight and survival condition simultaneously.
2) medicine sapindoside B (II) is prepared by the basic hydrolysis of Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms saponin(e second.The positive control medicine is Zorubicin (Doxorubicin).
3) measurement of tumor and volume calculation:, measured once, and measured the major diameter (L) and the minor axis (W) of tumour respectively, in per 3 days according to formula V=L * W with vernier caliper measurement mouse Subcutaneous tumor
2* 0.52 calculates gross tumor volume.Be calculated as follows tumour inhibiting rate:
Tumour inhibiting rate=[(the average knurl volume of the average knurl volume-experimental group of control group)/average knurl volume of control group] * 100%
Experimental result is seen Fig. 1.The basic hydrolysis product Compound I I of The compounds of this invention has tangible anti-tumor activity, inhibition rate of tumor growth to the Lewis tumor-bearing mice is 52.7%, be higher than positive control medicine Zorubicin (30.7%), and to the not obviously influence of body weight of tumor-bearing mice, to the also not obviously damage of organ of normal mouse.
The basic hydrolysis product Compound I I of Fig. 1 The compounds of this invention I is to the effect of mouse tumor growth-inhibiting
Embodiment
Embodiment 1
Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms honeysuckle medicinal material (dry flower) 5kg, with 10 times of amount 90%, 80% and 70% each refluxing extraction of ethanol once, each 3h merges No. three times extracting solution respectively, and being evaporated to does not have alcohol; Filter or high speed centrifugation, after macroporous resin fully adsorbs on filtrate or the centrifuged supernatant, successively water, 30% ethanol, that 70% ethanol liquid is eluted to elutriant is closely colourless, collects 70% ethanol liquid elutriant, evaporated under reduced pressure obtains the about 1.5kg in Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms total saponins position.This position medicinal extract dissolve with methanol, add about 1.5kg silica gel (200-300 order) and mix thoroughly, grind, last silica gel column chromatography is with chloroform-methanol system (20: 1,15: 1,10: 1,9: 2,8: 2.5,7: 3.5,1: 1), every 500ml is a flow point, altogether 72 flow points.Concentrating under reduced pressure, enriched product detects through thin-layer chromatography, merges similar flow point, obtains 1-10,11-18,19-25,26-34,35-72 totally five parts (Fraction1-Fraction 5).Get the dissolving of 70g Fraction 4 usefulness 50% methanol-water, last RP-C
18ODS reverse phase silica gel post, 55% methanol-water wash-out is collected 64 flow points, concentrating under reduced pressure, enriched product detects through thin-layer chromatography, merges identical flow point, obtains four parts (FractionA1-D1) altogether.FractionB1 obtains compound III (2.5g) through Sephadex LH-20 post 70% methanol-water wash-out.
Structure elucidation:
Compound III, white amorphous powder, 214～215 ℃ of m p, [α]
D 20-37.35 ° (c 0.5, and MeOH), TLC Vanillin-vitriol oil test solution heating displaing amaranth becomes blueness after several minutes, and Molish reaction and Liebermann-Burchard reaction are all positive, and prompting may be triterpene saponin componds.The thin layer acid hydrolysis: saponin(e takes a morsel, be dissolved in methyl alcohol, put on efficient thin layer plate, place concentrated hydrochloric acid steam 12h, volatilize concentrated hydrochloric acid, going up each monose reference substance again, is that developping agent launches with chloroform-methanol-water (16: 9: 2), uses chloroform-methanol-water (30: 12: 4 again, lower floor, every 9mL adds 1mL acetic acid) the secondary expansion, the colour developing of aniline-phthalic acid solution can detect glucose, pectinose, wood sugar and rhamnosyl.High resolution mass spectrum: 1199.5887[M+Na]
+, in conjunction with
1H NMR,
13C NMR and 2D NMR its molecular formula as can be known are C
57H
92O
25
1H NMR (C
5D
5N, 500MHz) δ: 6.30 (1H, br s), 6.25 (1H, d, J=8.1Hz), 5.31 (1H, d, J=7.6Hz), 5.05 (1H, d, J=6.6Hz), 4.90 (1H, d J=7.1Hz) are followed successively by the anomeric proton signal of rhamnosyl, glucose, wood sugar, pectinose and wood sugar, this result obtains the hsqc spectrum checking, and 5.38 (1H, br s) are 12 alkene hydrogen proton signals, 1.20,1.12,1.10,0.98,0.86,0.84 (each 3H, s) be 6 methyl proton signals, 1.54 (3H, d J=6.2Hz) are 6 methyl proton signals of rhamnosyl.
New saponin(e (III) of table 2 and known compound decaisoside E (IV)
13C NMR composes (C
5D
5N, 125MHz, δ, ppm)
13Show 57 carbon signals among the C NMR altogether, comprise carbon signal on 30 aglycon carbon signals and 27 sugar.Wherein aglycon carbon signal ivy aglycon basically identical, and C-3 position hydroxyl and C-28 carboxyl form disaccharide chain saponin(e all by glycosidation.Carbon signal (table 2) on comparative compound III and the known compound decaisodie E sugar, find the carbon signal unanimity in both C-3 position sugar chains of chemical combination, so infer that Compound I may contain 3-O-β-D-xylopyranosyl (1 → 3)-α-L-rhamnopyranosyl (1 → 2)-α-L-arabopyranose based structures segment; Then there is the chemical shift of one group of sugar to exist in the sugar chain of C-28 position than big-difference, and with document [Kim J.S., Shim S.H., Chae S., et al..Chem.Pharm.Bull.[J], 2005,53 (6): 696-700] chemical shift unanimity in the C-28 position sugar chain of compound 6 in may contain 28-O-β-D-xylopyranosyl-(1 → 4)-β-D-glucopyranosyl ester glycosides structure fragment so infer the I compound.
Comprehensive above the analysis, the structure of compound III is defined as 3-O-β-D-xylopyranosyl-(1 → 3)-α-L-rhamnopyranosyl-(1 → 2)-α-L-arabopyranose base-hederagenin-28-O-β-D-xylopyranosyl-(1 → 4)-β-D-glucopyranosyl ester glycosides, by literature search, be a new compound, called after Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms saponin(e second (Fulvotomentoside B).
Its chemical structure as shown in the formula:
Embodiment 2
Get 2g Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms saponin(e second, add 5%NaOH solution 20mL,, put coldly, add dense HCL and regulate pH value to 4～5 in 60 ℃ of water-bath refluxing extraction 2h.Adding water-saturated n-butanol solution (1: 1, v/v) extraction is 3 times, merges butanol extraction liquid, and decompression and solvent recovery gets n-butyl alcohol extract to doing.N-butyl alcohol extract is splined on silicagel column, with ethyl acetate: methyl alcohol: water (5: 1: 0.1) wash-out, altogether 45 flow points, with concentrating under reduced pressure, merge wherein 10～40 flow points with rotary evaporation, white powder, be sapindoside B (1.1g).
Claims (6)
1, the saponin compound of following general formula (III):
2, the preparation method of the saponin compound of claim 1 may further comprise the steps:
With the Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms dry flower is raw material, use the 30-90% alcohol reflux, extracting solution is evaporated to does not have the alcohol flavor, filters or high speed centrifugation, macroporous resin column on filtrate or the centrifuged supernatant, fully after the absorption,, merge 50-70% ethanol liquid elutriant with ethanol one water system gradient elution, evaporated under reduced pressure, obtain the Lonicera fulvotnetosa Hsu et S. C. Cheng. Ms total saponins, total saponins is again through silica gel column chromatography, anti-phase C18 post and the further separation and purification of dextrane gel column chromatography, promptly.
3, the preparation method of claim 2, wherein macroporous resin is D101, AB-8, HPD100, HPD300 or D1 type macroporous resin.
4, the saponin compound of claim 1 is used to prepare the purposes of antitumor drug (II)
5, the purposes of claim 4, wherein saponin compound prepares antitumor drug (II) by following method: compound III adds 1～8% potassium hydroxide or aqueous sodium hydroxide solution, warm or refluxing extraction 2～6h in 40～80 ℃ of water-baths, add sour adjust pH to 4～6 after cold, use n-butanol extraction again, after extraction liquid reclaims solvent, carry out silica gel column chromatography, use ethyl acetate: methyl alcohol: the water system wash-out, concentrate, promptly get Compound I I.
6, the purposes of claim 5, wherein ethyl acetate: methyl alcohol: water volume ratio is 5: 1: 0.1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710135566A CN100584856C (en) | 2007-11-16 | 2007-11-16 | The purposes of a kind of Hederagenin, its preparation method and preparation antitumor drug thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710135566A CN100584856C (en) | 2007-11-16 | 2007-11-16 | The purposes of a kind of Hederagenin, its preparation method and preparation antitumor drug thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101157714A CN101157714A (en) | 2008-04-09 |
| CN100584856C true CN100584856C (en) | 2010-01-27 |
Family
ID=39305962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710135566A Expired - Fee Related CN100584856C (en) | 2007-11-16 | 2007-11-16 | The purposes of a kind of Hederagenin, its preparation method and preparation antitumor drug thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100584856C (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101406509B (en) * | 2008-11-28 | 2011-08-31 | 江苏省中国科学院植物研究所 | Lonicera confusa extract and preparation method and application thereof |
| WO2011085544A1 (en) * | 2010-01-13 | 2011-07-21 | 安徽辉克药业有限公司 | Compounds which effecttively remove tumor or cancer cell |
| CN102391349B (en) * | 2011-09-23 | 2014-07-02 | 江苏省中国科学院植物研究所 | New honeysuckle lonimacranthoide and preparation method and application thereof |
| CN102627683A (en) * | 2012-03-20 | 2012-08-08 | 苏州世林医药技术发展有限公司 | Triterpenoid saponin compounds with antitumor effects |
| CN104688798B (en) * | 2015-03-24 | 2018-09-21 | 山东省医学科学院药物研究所 | A kind of preparation method and application of rosy clouds grass extract |
| KR102118433B1 (en) | 2018-05-04 | 2020-06-03 | 백주연 | Composition comprising extract of Anemone raddeana, Lonicera species and Aralia elata including high concentrated saponin of anticancer activity for preventing or treating cancer and producing method the same |
| CN110974834A (en) * | 2019-12-02 | 2020-04-10 | 贵州中医药大学 | Application of Lonicera fulvidraco acid hydrolysate in pharmacy and preparation method thereof |
-
2007
- 2007-11-16 CN CN200710135566A patent/CN100584856C/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 黄褐毛忍冬化学成分的研究. 茅青等.药学学报，第24卷第4期. 1989 |
| 黄褐毛忍冬化学成分的研究. 茅青等.药学学报，第24卷第4期. 1989 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101157714A (en) | 2008-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100584856C (en) | The purposes of a kind of Hederagenin, its preparation method and preparation antitumor drug thereof | |
| CN101392015B (en) | Triterpene saponin in camellia seeds, preparation method and medical use thereof | |
| CN101242850A (en) | Composition, function and use of xanthoceras sorbifolia extract and compound isolated from same, method for preparing same | |
| CN101279964B (en) | Guaiane type sesquiterpenes, preparation and medical use thereof | |
| CN102219821A (en) | Cardiac glycoside compounds and antitumor application thereof | |
| CN104151373B (en) | Lignan glycoside compounds and preparation method thereof | |
| EP3412679A1 (en) | Baicalin magnesium, preparation method thereof and application of same | |
| CN106138627A (en) | The preparation method of monomeric substance and application in preparation treatment Alzheimer disease drugs thereof in China's Trillium or Paris Linnaeus(Paris L.) medical material | |
| CN101768202A (en) | Preparing method of high purity sarsasapogenin in rhizoma anemarrhenae and derivatives thereof, and medical new application thereof | |
| CA2435524C (en) | Use of hederagenin 3-o-.alpha.-l-rhamnopyranosyl((1->2)-[.beta.-d-glucopyranosyl(1->4)]-.alpha.-l-arabinopyranoside or an extract from pulsatillae radix containing the same as a therapeutic agent for solid tumors | |
| CN110256512A (en) | A kind of alpha-glucosidase restrainer extracted from short raw Potentilla bifurca | |
| CN106866776A (en) | New steroid saponin compound and its application | |
| CN101880306B (en) | Stauntonia brachyanthera Hand-Mazz saponins components as well as preparation method and application thereof | |
| CN102093453B (en) | Method for preparing 20(R)-25-hydroxy-dammarane type-3beta,12beta,20-triols | |
| CN105640971B (en) | Application of the total saposins in terms of preparing auxiliary hyperglycemic drug in prematurity Fructus Monordicae extract | |
| CN101229212A (en) | Lonicera fulvotnetosa total secondary saponin position, preparing method and antitumor uses thereof | |
| KR100316567B1 (en) | Anti-cancer ginseng saponin, method for producing the same, and anticancer composition containing the same as an active ingredient | |
| CN102942605A (en) | Preparation method and application of Jasminum lanceolarium medium-ring iridoids | |
| CN102408464A (en) | Novel notriterpenoid saponin compound and preparation method and application thereof | |
| CN103232518B (en) | Triterpene saponins compound and its production and use falls in a kind of new Salicornia Bigelovii Torr. | |
| CN101601699A (en) | The preparation technology of kostelezkya virginica saponin and purposes | |
| CN102295677B (en) | In the salicornia europaeal of North America, triterpenoid saponin and its production and use falls in one | |
| CN100584837C (en) | Hydroxy stilbene kind compound and its preparation method and application | |
| CN102408466A (en) | New Salicomia europaea saponin and preparation method and applications thereof | |
| CN101468950B (en) | Novel compound separated from immature exocarp of Juglans mandshurica Maxim, and preparation and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100127 |